Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ladenstein Ruth; Poetschger Ulrike; Valteau-Couanet Dominique; Luksch Roberto; Castel Victoria; Yaniv Isaac; Laureys Genevieve; Brock Penelope; Michon Jean Marie; Owens Cormac; Trahair Toby; Chan Godfrey Chi Fung; Ruud Ellen; Schroeder Henrik; Popovic Maja Beck; Schreier Guenter; Loibner Hans; Ambros Peter; Holmes Keith; Castellani Maria Rita; Gaze Mark N.; Garaventa Alberto; Pearson Andrew D. J.; Lode Holger N.

首页> 外文期刊>The lancet oncology >Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

【24h】

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

机译：白细胞介素2具有抗GD2抗体CH14.18 / CHO（DINUTUXIMABβ）高危神经母细胞瘤（HR-NBL1 / SIOPEN）：多期，随机，第3阶段试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab beta alone in children and young people with high-risk neuroblastoma.

机译：背景技术与嵌合抗GD2单克隆抗体Dinutuximab的免疫疗法联合交替的粒细胞 - 巨噬细胞刺激因子和静脉内白细胞介素-2（IL-2），改善了高危神经母细胞瘤患者的存活。我们的目标是在用CH14.18 / CHO（DINOUTUXIMABβ）和皮下IL-2治疗后评估无事的存活，而单独在儿童和青少年患有高危神经母细胞瘤的儿童和青少年。

著录项

来源
《The lancet oncology》 |2018年第12期|共13页
作者
Ladenstein Ruth; Poetschger Ulrike; Valteau-Couanet Dominique; Luksch Roberto; Castel Victoria; Yaniv Isaac; Laureys Genevieve; Brock Penelope; Michon Jean Marie; Owens Cormac; Trahair Toby; Chan Godfrey Chi Fung; Ruud Ellen; Schroeder Henrik; Popovic Maja Beck; Schreier Guenter; Loibner Hans; Ambros Peter; Holmes Keith; Castellani Maria Rita; Gaze Mark N.; Garaventa Alberto; Pearson Andrew D. J.; Lode Holger N.;
展开▼
作者单位

St Anna Childrens Hosp Vienna Austria;

Childrens Canc Res Inst Dept Studies &

Stat &

Integrated Res Vienna Austria;

Paris Sud Univ Gustave Roussy Children &

Adolescent Oncol Dept Paris France;

Ist Nazl Tumori Fdn IRCCS Dept Ematol &

Oncoematol Milan Italy;

Hosp Univ &

Politecn La Fe Pediat Oncol Unit Valencia Spain;

Tel Aviv Univ Pediat Oncol Unit Schneider Childrens Med Ctr Israel Sackler Fac Med Petah Tiqwa;

Univ Hosp Ghent Dept Pediat Hematol Oncol &

Stem Cell Transplanta Ghent Belgium;

Great Ormond St Hosp Sick Children Dept Pediat Oncol London England;

Inst Curie Children Adolescent &

Young Adults Dept Paris France;

Our Ladys Childrens Hosp Dept Haematooncol Dublin Ireland;

Sydney Childrens Hosp Kids Canc Ctr Randwick NSW Australia;

Queen Mary Hosp Dept Paediat &

Adolescent Med Hong Kong Hong Kong Peoples R China;

Natl Hosp Norway Dept Paediat Med Oslo Norway;

Univ Hosp Aarhus Dept Paediat Aarhus Denmark;

Univ Hosp Lausanne Dept Paediat &

Paediat Surg Paediat Haematol Oncol Unit Lausanne Switzerland;

AIT Austrian Inst Technol GmbH Ctr Hlth &

Bioresources Graz Austria;

Apeiron Biol AG Vienna Austria;

Childrens Canc Res Inst Dept Biol Vienna Austria;

St George Hosp Dept Paediat Surg London England;

Ist Nazl Tumori Fdn IRCCS Dept Ematol &

Oncoematol Milan Italy;

Univ Coll London Hosp Univ Coll London Hosp NHS Fdn Trust Dept Oncol Natl Inst Hlth Res Biomed;

Ist Giannina Gaslini Oncol Unit Genoa Italy;

Royal Marsden Hosp Inst Canc Res Oak Ctr Children &

Young People Paediat &

Adolescent Drug Dev;

Univ Med Greifswald Paediat Haematol Oncol Dept Greifswald Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial [J] . Ladenstein Ruth, Poetschger Ulrike, Valteau-Couanet Dominique, The lancet oncology . 2018,第12期

机译：白细胞介素2具有抗GD2抗体CH14.18 / CHO（DINUTUXIMABβ）高危神经母细胞瘤（HR-NBL1 / SIOPEN）：多期，随机，第3阶段试验
2. Immunotherapy with Anti-GD2 Antibody ch14.18/CHO +/- IL2 within the HR-NBL1/SIOPEN Trial Improves Outcome of High-Risk Neuroblastoma Patients Compared to Historical Controls [J] . Ladenstein R., Poetschger U., Valteau-Couanet D., Pediatric blood & cancer . 2018,第Suppla2期

机译：HR-NBL1 / Siopen试验中的抗GD2抗体CH14.18 / CHO +/-IL2的免疫疗法改善了高危神经母细胞瘤患者的结果与历史控制相比
3. Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients [J] . Ladenstein R., Poetschger U., Valteau-Couanet D., Pediatric blood & cancer . 2019,第S4期

机译：HR-NBL1 / SIOPEN试验随机化剂量减少皮下白细胞介素2（SCIL2）的早期结果与高危神经母细胞瘤患者的DINOUTUXIMABβ（DB）长期输注（LTI）
4. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) [O] . Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, 2020

机译：在基于SIOPEN的高危神经母细胞瘤1试验（HR-NBL1）中使用基于Dinutuximab Beta的免疫治疗的研究
5. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) [O] . 2020

机译：Dinutuximabβ的免疫治疗在Siopen高危神经母细胞瘤1试验中的作用调查（HR-NBL1）

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅